Trending Now
Is Elon Musk done selling TSLA stock to cover Twitter sale
Tesla Inc (TSLA) stock is currently trading at $191.30 down over 15% in the past 5 trading days. So what caused the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Clinches $450 Million Deal From The US...
The Trump administration awarded a $450 million contract under ‘Operation Warp Speed’ to Regeneron Pharmaceuticals Inc (NASDAQ:REGN)(RPC) to develop and quickly distribute the antibody...
MAKE IT MODERN
LATEST REVIEWS
Earnings Spotlight: Microsoft’s Anticipated Quarterly Performance and Strategic Moves (MSFT)
Microsoft (MSFT) is poised to unveil its earnings after the market closes Tuesday, with a management conference call scheduled for 5:30 p.m.
MAKE IT MODERN
PERFORMANCE TRAINING
Adptimmune Therapeutics Plc (NASDAQ: ADAP) Releases Encouraging Data From SURPASS Study in Multiple Tumors
Adptimmune Therapeutics Plc (NASDAQ: ADAP) has announced its latest data from the first phase SURPASS study in multiple solid tumors. The data will be...
A Look at Top Recession-Proof Stocks in the Alcohol Space (DEO, KEGS, STZ, BF.B,...
As noted by major Wall Street houses of late, the odds of a US (and possibly global) recession have jumped over recent...
OncoCyte Corp (NYSEAMERICAN:OCX) and the Guardian Research Network® Collaborate to Establish an Integrated Platform...
Cancer is a leading cause of death in the United States. Victims and their families, employers, and insurance companies spend over 150 billion dollars...
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Commences Phase 2A Study Evaluating PH94B in Anxiety Treatment
VistaGen Therapeutics Inc. (NASDAQ: VTGN) has announced the commencement of phase 2A clinical study to assess safety, tolerability, and efficacy of PH94B as a...
Investing in Disruptive Technology: The Healthcare Opportunity (USAQ, PLTR, EXAS, MDT, VEEV, CERN)
No industry is safe from the disruptive encroachment of technological advances. None.
And those advances are happening at a...
MAKE IT MODERN
